Blueprint Medicines Corp Stock Cash And Equivalents
| BPMC Stock | USD 95.10 0.47 0.50% |
Blueprint Medicines Corp fundamentals help investors to digest information that contributes to Blueprint Medicines' financial success or failures. It also enables traders to predict the movement of Blueprint Stock. The fundamental analysis module provides a way to measure Blueprint Medicines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Blueprint Medicines stock.
Blueprint | Cash And Equivalents |
Blueprint Medicines Corp Company Cash And Equivalents Analysis
Blueprint Medicines' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Blueprint Medicines Cash And Equivalents | 853.11 M |
Most of Blueprint Medicines' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Blueprint Medicines Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Blueprint Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Blueprint Medicines is extremely important. It helps to project a fair market value of Blueprint Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Blueprint Medicines' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Blueprint Medicines' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Blueprint Medicines' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Blueprint Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Blueprint Medicines Corp has 853.11 M in Cash And Equivalents. This is 3.93% higher than that of the Biotechnology sector and 90.8% higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 68.43% higher than that of the company.
Blueprint Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Blueprint Medicines' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Blueprint Medicines could also be used in its relative valuation, which is a method of valuing Blueprint Medicines by comparing valuation metrics of similar companies.Blueprint Medicines is currently under evaluation in cash and equivalents category among its peers.
Blueprint Medicines ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Blueprint Medicines' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Blueprint Medicines' managers, analysts, and investors.Environmental | Governance | Social |
Blueprint Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 5.78 B | ||||
| Shares Outstanding | 63.53 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 99.10 % | ||||
| Number Of Shares Shorted | 3.91 M | ||||
| Price To Earning | 7.93 X | ||||
| Price To Book | 19.29 X | ||||
| Price To Sales | 13.91 X | ||||
| Revenue | 249.38 M | ||||
| Gross Profit | 177.28 M | ||||
| EBITDA | (470.36 M) | ||||
| Net Income | (506.98 M) | ||||
| Cash And Equivalents | 853.11 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 774.12 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 6.00 X | ||||
| Book Value Per Share | 4.93 X | ||||
| Cash Flow From Operations | (436.85 M) | ||||
| Short Ratio | 5.59 X | ||||
| Earnings Per Share | (2.09) X | ||||
| Target Price | 125.58 | ||||
| Number Of Employees | 638 | ||||
| Beta | 0.59 | ||||
| Market Capitalization | 6.04 B | ||||
| Total Asset | 1.05 B | ||||
| Retained Earnings | (2.34 B) | ||||
| Working Capital | 593.47 M | ||||
| Current Asset | 170.42 M | ||||
| Current Liabilities | 18.64 M | ||||
| Net Asset | 1.05 B |
About Blueprint Medicines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Blueprint Medicines Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Blueprint Medicines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Blueprint Medicines Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Blueprint Medicines Piotroski F Score and Blueprint Medicines Altman Z Score analysis. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.